SLC5A2 and diabetes mellitus: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) are among the emerging classes of antidiabetic medications for the management of type 2 diabetes mellitus (T2DM).